Tpl2 kinase inhibitors (Pfizer)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameTpl2 kinase inhibitors (Pfizer)
Drug Alias NameCOT kinase inhibitors (Wyeth)Tpl2 kinase inhibitors (Wyeth)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase kinase kinase 8 inhibitors
TargetsMitogen-activated protein kinase kinase kinase 8
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWyeth Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWyeth LlcPfizer Inc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A